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DObjectives: Long-term thromboembolic and hemorrhagic outcomes after mechanical valve replacement have
been well described; however, few studies have described these outcomes after valve replacement with the
On-X mechanical prosthesis (On-X Life Technologies, Inc, Austin, Tex).
Methods: Between 2003 and 2008, 737 patients underwent either aortic valve replacement (n ¼ 400), mitral
valve replacement (n ¼ 282), or double-valve replacement (n ¼ 55). Longitudinal performance, freedom evalu-
ation, and risk analysis were assessed with regard to major thromboembolism and hemorrhage. Risk modeling
was performed with 16 variables inclusive of age, atrial fibrillation, concomitant coronary artery bypass grafting,
New York Heart Association class, and ventricular dysfunction.
Results: Early mortality was 2.5% (n ¼ 10) for aortic valve replacement and 3.2% (n ¼ 9) for mitral valve re-
placement. Late mortality for aortic valve replacement was 4.8% per patient-year and 6.0% per patient-year for
mitral valve replacement. Five-year freedom from major thromboembolism was 96.5%  1.2% for aortic valve
replacement and 97.7% 0.9% for mitral valve replacement. Five-year freedom from hemorrhage was 93.6%
1.8% for aortic valve replacement and 95.7% 1.5% for mitral valve replacement. Concomitant coronary artery
bypass grafting was predictive of major thromboembolism after aortic valve replacement (hazard ratio, 5.3;
P ¼ .02) and antithrombotic hemorrhage after mitral valve replacement (hazard ratio, 4.7; P ¼ .03). No other in-
dependent predictors of major thromboembolism or hemorrhage were identified. One thrombosed mitral prosthe-
sis was observed after deliberate discontinuation of anticoagulation. The major thromboembolic events occurred
with variation of international normalized ratio levels inclusive of subtherapeutic levels. The majority of hemor-
rhagic events occurred with high international normalized ratio levels.
Conclusions: The On-X mechanical prosthesis provides favorable intermediate-term results with regard to major
thromboembolism and hemorrhage. (J Thorac Cardiovasc Surg 2010;140:1053-8)Supplemental material is available online.
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The Journal of Thoracic and Carvalves because of the design of the pyrolytic carbon leaflets
and inlet flare.1,2 These technologic improvements have been
hypothesized to limit morbid events in patients. Several
studies from North America, Europe, and South Africa
have described favorable clinical outcomes after On-X valve
replacement since its first implantation in 1996.3-13
Reported thromboembolic and hemorrhagic complication
rates after valve replacement with the On-X prosthesis are
low. After aortic valve replacement (AVR), reported 2-year
freedom frommajor thromboembolism or hemorrhage range
from 96% to 98%.8,9 Similar results were also observed
after implantation in the mitral valve position.8,9
Although well designed, these studies have been limited
by sample size in addition to a short duration of follow-up.
Data describing outcomes after valve replacement have of-
ten included multiple contributing centers; consequently,
there has been relative heterogeneity in regard to operative
and postoperative management. Furthermore, although the
On-X valve has been purported to confer fewer morbid
events because of improved hemodynamics, few data are
available describing major thromboembolism and hemor-
rhage over the intermediate term.diovascular Surgery c Volume 140, Number 5 1053
TABLE 1. Preoperative and operative characteristics
Characteristic
AVR
(n ¼ 400)
MVR
(n ¼ 282)
P
value
Demographics
Age (y) 55.2  10.6 58.7  10.7 <.001
Female sex 107 (27%) 179 (64%) <.001
Cardiac comorbidity
COPD 12 (3%) 11 (4%) .7
Current smoker 64 (16%) 36 (13%) .2
Diabetes mellitus 43 (11%) 37 (13%) .3
LV ejection fraction .5
<35% 19 (5%) 19 (7%)
35% to 51% 61 (15%) 42 (15%)
>51% 320 (80%) 221 (78%)
NYHA class III–IV 225 (56%) 203 (72%) <.001
Permanent atrial fibrillation 25 (6%) 79 (28%) <.001
Previous CABG 26 (7%) 25 (9%) .2
Previous valve replacement 30 (8%) 23 (8%) .8
Renal failure 43 (11%) 34 (12%) .6
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CNS ¼ central nervous system
HR ¼ hazard ratio
INR ¼ international normalized ratio
MVR ¼ mitral valve replacement
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DTherefore we performed a prospective, observational,
multicenter study involving 737 patients who underwent ei-
ther AVR,mitral valve replacement (MVR), or double-valve
replacement. The objective of this study was to evaluate the
performance of the On-X mechanical prosthesis in regard to
(1) major thromboembolism, (2) hemorrhage, and (3) com-
posites of valve-related complications.Operative characteristics
CABG 62 (16%) 28 (10%) .03
Operative status .9
Elective/urgent 390 (98%) 274 (97%)
Emergency 10 (3%) 8 (3%)
Thirty-day mortality 10 (3%) 9 (3%) .6
AVR, Aortic valve replacement; MVR, mitral valve replacement; COPD, chronic ob-
structive pulmonary disease; LV, left ventricular; NYHA, New York Heart Association
functional class; CABG, coronary artery bypass grafting.MATERIALS AND METHODS
Funding Support and Ethics Approval
On-X Life Technologies, Inc (formerly known as MCRI), provides un-
restricted financial support to the University of Ottawa Heart Institute Valve
Clinic and the University of British Columbia Cardiac Valve Database. Co-
author Dr Jamieson receives speakers’ bureau support from On-X Life
Technologies and does not receive financial support as the international
principal investigator for the Prospective Randomized On-X Versus St
Jude Medical Evaluation Trial. The University of Ottawa Heart Institute
has existing ethics approval from the local research ethics board to publish
prospectively collected data after heart valve replacement. As such, individ-
ual patient consent was waived. The University of British Columbia Cardiac
Valve Database receives annual renewal from the University of British Co-
lumbia Clinical Research Ethics Board, whichmanages the patient informed
consent process.
Patient Population
Seven hundred thirty-seven patients underwent AVR, (n ¼ 400), MVR
(n¼ 282), or double-valve replacement (n¼ 55) with the On-X mechanical
prosthesis between 2002 and 2008 at the University of Ottawa Heart Insti-
tute, Ottawa, Ontario, Canada, and the University of British Columbia, Van-
couver, British Columbia, Canada. Patients receiving multiple-valve
replacement were not included in the subsequent data analysis. Baseline
patients’ characteristics are described in Table 1.
Surgical Technique
Standard surgical technique included use of median sternotomy, cardio-
pulmonary bypass, and mild systemic hypothermia (32C–34C). Blood
cardioplegia was used for myocardial protection.
For implantation in the aortic position, braided sutures, either pledgetted
or nonpledgetted, were used. For implantation in the mitral position, the 25-
mmMCRI On-X mitral valve was implanted into patients with annuli sized
at 29 mm or less, whereas the 33-mm version, with the expanded sewing
ring, was implanted into annuli sized at greater than 29 mm. Braided sutures
with pledgets were used for implantation in the mitral position. Implanted
valve sizes are described in Table E1.
Follow-up
All patients undergoing valve replacement are prospectively followed by
the University of Ottawa Heart Valve Clinic and the University of British1054 The Journal of Thoracic and Cardiovascular SurColumbia Cardiac Valve Database. This includes annual assessments for
prosthesis-related complications outlined by the ‘‘Guidelines for reporting
mortality and morbidity after cardiac valve interventions.’’14 Follow-up
was obtained through clinic visits, telephone interviews, or vital statistics
registries. Total follow-up was for 1903 patient-years (1066 patient-years
after AVR and 837 patient-years after MVR) and was 100% complete for
all living patients (mean, 2.8  0.7 years).
Postoperative Management
The target international normalized ratio (INR) was between 2.0 and 2.5
after AVR and between 2.0 and 3.0 after MVR. The presence of concomi-
tant atrial fibrillation did not augment the recommended therapeutic INR
range. Patients in this series were not part of the ongoing Prospective Ran-
domized On-XAnticoagulation Clinical Trial, investigating the effect of an-
ticoagulation with a lower dose of warfarin or antiplatelet therapy alone.
Home INR monitoring was also not used in this study.
Statistical Analysis
Baseline characteristics were compared between patients undergoing
AVR or MVR by using the c2 and Fisher’s exact tests when the frequency
was less than 5. Continuous variables were assessed by using the Student’s t
test when normally distributed, and the Wilcoxon rank sum test when data
were skewed.
The Kaplan–Meier method was used to assess freedom from valve-
related complications.14 Valve-related complications and composites were
also expressed as linearized occurrence rates. Predictors of outcome, namely
major thromboembolism and hemorrhage, valve-related reoperation, valve-
related mortality, and late mortality, were determined by using separate
semiparametric multivariable Cox proportional hazard models. Sixteen var-
iables were used to assess predictors of outcome inclusive of age, atrial
fibrillation, chronic obstructive pulmonary disease, concomitant coronarygery c November 2010
TABLE 2. Valve-related complications and composites
Linearized occurrence rates
(% per patient-year [95%
confidence interval])
AVR MVR
Major thromboembolism 0.94 (0.36–1.52) 0.72 (0.15–1.29)
Hemorrhage 1.60 (0.84–2.35) 1.20 (0–3.05)
Valve-related reoperation 0.38 (0.01–0.74) 0.24 (0–1.40)
Valve-related mortality 0.19 (0.07–0.44) 0.12 (0.11–0.35)
Chan et al Acquired Cardiovascular Diseaseartery bypass grafting (CABG), diabetes mellitus, sex, implanted valve size,
indexed effective orifice area, preoperative left ventricular ejection fraction,
preoperative New York Heart Association functional class, preoperative re-
nal dysfunction, preoperative smoking, prior cerebrovascular accident, prior
CABG, prior heart valve replacement, and status of operation. These vari-
ables were defined according to the established definitions of the Society
of Thoracic Surgeons National Database. Multivariate modeling was per-
formed to determine independent predictors of outcome. Final multivariate
models were constructed by including covariates with a P value of less than
.25 on univariate screening. All analyses were performed with SAS statisti-
cal software (SAS version 9.1; SAS Institute, Inc, Cary, NC).
AVR, Aortic valve replacement; MVR, mitral valve replacement.
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DRESULTS
Preoperative and Operative Characteristics
Table 1 describes the preoperative and operative charac-
teristics of patients implanted with the On-X prosthesis in
the aortic or mitral position. Patients undergoing mechanical
MVR were older than patients undergoing AVR (58.7 
10.7 vs 55.2  10.6 years, P<.001). Overall, the incidence
of preoperative renal dysfunction and diabetes was 12%
(77/682) and 13% (80/682), respectively. Patients undergo-
ing AVRwere more likely than patients undergoingMVR to
receive concomitant CABG (62/400 vs 28/282, P ¼ .03).
Overall, 30-day mortality was 3% (19/682). Twenty-six per-
cent of patients underwent AVR with prostheses of 21 mm
or less, whereas 43% of patients underwent MVR with the
25-mm prosthesis (Table E1).Outcomes
Major thromboembolism. There were 16 major thrombo-
embolic events that occurred in 15 patients after AVR
(n ¼ 10) and MVR (n ¼ 6). Among the 10 major thrombo-
embolic events in 9 patients after AVR, the mean INR at
the time of the clinical event was 1.7  0.7. Seven of the
10 major thromboembolic events occurred in patients with
INRs of less than 2.0. Six major thromboembolic events
were observed in 6 patients after MVR. The median INR atFIGURE 1. Actuarial freedom frommajor thromboembolism (aortic valve
replacement [AVR] and mitral valve replacement [MVR]). SE, Standard
error.
The Journal of Thoracic and Carthe time of the clinical event was 1.9. One incidence of valve
thrombosis was observed after MVR. This occurred in a pa-
tient within 60 days of the initial MVR after deliberate dis-
continuation of warfarin. This patient subsequently
underwent successful urgent redoMVRwith a bioprosthesis.
Five-year actuarial freedom frommajor thromboembolism
was 96.5%  1.2% and 97.7%  0.9% after AVR and
MVR, respectively (Figure 1). Accordingly, linearized oc-
currence rates were 0.94% per patient-year and 0.72% per
patient-year after AVR and MVR, respectively (Table 2).
Although a variety of univariate predictors ofmajor thrombo-
embolism were identified after AVR, concomitant CABG
was the only multivariate predictor (hazard ratio [HR], 5.3;
P ¼ .02; Tables E2 and E3). No independent multivariate
predictors of major thromboembolism were identified after
MVR (Table E4).
Antithrombotic hemorrhage. Twenty-seven antithrom-
botic hemorrhagic events occurred in 26 patients after AVR
(n ¼ 17 events in 16 patients) and MVR (n ¼ 10 events in
10 patients). In patients with antithrombotic hemorrhage
after AVR, themost common site of bleedingwas gastrointes-
tinal (n¼ 7), followed by systemic bleeding (n¼ 7 events in
6 patients) and central nervous system bleeding (CNS; n¼ 3).
In patients with CNS hemorrhage, 2 completely recovered,
and 1 died.FIGURE 2. Actuarial freedom from hemorrhage (aortic valve replacement
[AVR] and mitral valve replacement [MVR]). SE, Standard error.
diovascular Surgery c Volume 140, Number 5 1055
TABLE 3. Summary of literature regarding outcomes after bileaflet mechanical valve replacement
Outcome (% per patient-year)
Valve prosthesis Hemorrhage Major TE Valve-related reoperation Valve-related mortality
On-X AVR 1.60 AVR 0.94 AVR 0.38 AVR 0.19
MVR 1.20 MVR 0.72 MVR 0.24 MVR 0.12
ATS
Emery and coworkers16 AVR 1.8 AVR 1.6 AVR 0.2 —
MVR 2.3 MVR 2.2 MVR 0.2
CarboMedics
Aagaard and coworkers17 AVR 2.6 AVR 0.74 — —
MVR 2.6 MVR 1.30
Jamieson and coworkers18 MVR 2.4 MVR 3.2 MVR 1.7 MVR 0.5
Jamieson and coworkers20 — — AVR 0.3 —
MVR 1.1
St Jude Medical
Emery and coworkers19 AVR 2.7 AVR 1.9 — —
MVR 2.7 MVR 2.8
Jamieson and coworkers18 MVR 0.9 MVR 2.0 MVR 1.1 MVR 0.7
CarboMedics/St Jude Medical
Chan and coworkers21 — — AVR 0.3 AVR 0.7
Jamieson and coworkers22 — — MVR 0.5 MVR 0.7
Jamieson and coworkers23
<65 y — AVR 1.5 — —
65 y — AVR 3.3 — —
TE, Thromboembolism; AVR, aortic valve replacement; MVR, mitral valve replacement; ATS, Advancing the Standard.
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DIn patients with postoperative hemorrhage after MVR, the
most common site of bleeding was also gastrointestinal
(n ¼ 5), followed by systemic bleeding (n ¼ 3) and CNS
bleeding (n ¼ 2). In the 2 cases of CNS hemorrhage after
MVR, 1 patient completely recovered, whereas the other
event was fatal. The mean INR at the time of the clinical
event was 5.2  2.6, with 9 of the 10 hemorrhagic events
occurring in patients with an INR of greater than 3.5.
Five-year actuarial freedom from antithrombotic hemor-
rhage was 93.6% 1.8% after AVR and 95.7% 1.5% af-
ter MVR (Figure 2). Chronic obstructive pulmonary disease
and previous cerebrovascular accident were predictive of
hemorrhage on univariate analysis; however, no multivariate
predictors of hemorrhage were identified after AVR (Tables
E2 and E3). In patients undergoing MVR, concomitant
CABG was predictive of hemorrhage on multivariate
analysis (HR, 4.6; P ¼ .04; Table E4).
Valve-related reoperation. Actuarial freedom from valve-
related reoperation at 5 years was 98.4% 0.9% after AVR
and 99.0%  0.7% after MVR (Figure E1). Older patients
were less likely to require aortic valve reoperation (HR, 0.89
per increasing year; P ¼ .04; Table E3). No independent
predictors of valve-related reoperation were identified for
patients undergoing MVR (Table E4).
Valve-related mortality. In patients undergoing AVR,
5-year actuarial freedom from valve-related mortality was
99.5% 0.4%, with a corresponding linearized occurrence
rate of 0.19% per patient-year. Freedom from valve-related1056 The Journal of Thoracic and Cardiovascular Surmortality after MVR was 99.6%  0.4% at 5 years
(Figure E2). No independent predictors of valve-related
mortality were identified for patients undergoing AVR or
MVR (Tables E3 and E4).
Overall survival. Five-year actuarial survival was
91.5%  1.6% after AVR and 90.0%  2.0% after
MVR (Figure E3). Age and preoperative atrial fibrillation
were predictive of overall survival after AVR (Table E3),
whereas concomitant CABG, left ventricular ejection frac-
tion, prior CABG, and preoperative renal dysfunction were
predictive of overall survival after MVR.
DISCUSSION
In this study we prospectively followed a cohort of pa-
tients undergoing either AVR or MVR with the On-X pros-
thesis to determine its clinical performance in regard to (1)
major thromboembolism, (2) antithrombotic hemorrhage,
and (3) composites of valve-related complications. Notably,
this study was performed without specific control of postop-
erative INR. Instead, patients were managed by either the
primary physician or the treating cardiac surgeon according
to practice guidelines.15
Patients in this study were comparable in age to those of
other studies describing outcomes after mechanical valve re-
placement.3-13 Overall, 6% (38/682) of patients had
preoperative left ventricular ejection fraction of less than
35%, whereas concomitant CABG was performed in 13%
(80/682) of patients.gery c November 2010
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DNot surprisingly, patients with major thromboembolism
tended to have a subtherapeutic INR, whereas patients
with hemorrhagic events tended to have a supratherapeutic
INR.14 Five-year freedom from major thromboembolism
was 96.5%  1.2% for patients undergoing AVR and
97.7%  0.9% for patients undergoing MVR, whereas 5-
year freedom from antithrombotic hemorrhage was
93.6%  1.8% for patients undergoing AVR and
95.7% 1.5% for patients undergoing MVR. These results
correspond with previously reported 2- and 4-year outcomes
after On-X AVR and MVR.6,8,9
Accordingly, the linearized rates of major thromboembo-
lism and hemorrhage were 0.94% per patient-year and
1.60% per patient-year, respectively, after AVR and
0.72% per patient-year and 1.20% per patient-year, respec-
tively, after MVR. These results compared favorably with
previously published rates of major thromboembolism and
hemorrhage for other commercially available bileaflet me-
chanical heart valves (Table 3).16-23 In patients after AVR,
previously published rates for major thromboembolism
have ranged from 0.7% to 3.3% per patient-year and for
hemorrhage from 1.8% to 2.7% per patient-year (Table
3).16-19,23 After MVR, published linearized rates of major
thromboembolism and hemorrhage have ranged from
1.3% to 3.2% per patient-year and 0.9% to 2.7% per
patient-year, respectively.16-19
Concomitant CABG was predictive of major thromboem-
bolism after AVR and also of antithrombotic hemorrhage af-
ter MVR. Predictors for major thromboembolism or
antithrombotic hemorrhage have previously not been re-
ported for the On-X prosthesis.
Composites of valve-related complications were rare after
AVR or MVR with the On-X valve. Reoperation rates were
0.38% per patient-year after AVR and 0.24% per patient-
year after MVR, whereas valve-related mortality rates
were 0.19% per patient-year and 0.12% per patient-year af-
ter AVR and MVR, respectively. These are similar to previ-
ously reported rates for valve-related reoperation and valve-
related mortality.3-5,7,16,18,20-23
Limitations
This nonrandomized study describes data up to 8 years af-
ter On-X valve replacement, and therefore conclusions re-
garding the long-term performance of this valve cannot be
made. Linearized rates of event occurrence have been pre-
sented in this study; however, it is unclear whether event oc-
currence will remain constant over the long-term. Valve-
related hemorrhage and thromboembolism occur most fre-
quently within the first 6 months after valve surgery,24 and
therefore we believe that the linearized rates of event occur-
rence in this series are not an overestimate of the perfor-
mance of the On-X valve. Outcomes must be interpreted
in context, especially when comparisons are made with se-
ries published with longer follow-up.17,19,21,22 Also, INRThe Journal of Thoracic and Cartargets were set according to current treatment guidelines15
and were subject to management by primary physicians or
the treating cardiac surgeon. Major thromboembolic and
hemorrhagic events might therefore be the result of varia-
tions in anticoagulation.CONCLUSIONS
The On-X mechanical prosthesis provides favorable
intermediate-term results with regard to major thromboem-
bolism, hemorrhage, and composites of valve-related com-
plications.
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FIGURE E1. Actuarial freedom from valve-related reoperation (aortic
valve replacement [AVR] and mitral valve replacement [MVR]). SE, Stan-
dard error.
FIGURE E2. Actuarial freedom from valve-related mortality (aortic valve
replacement [AVR] and mitral valve replacement [MVR]). SE, Standard
error.
FIGURE E3. Overall survival (aortic valve replacement [AVR] and mitral
valve replacement [MVR]). SE, Standard error.
TABLE E1. Implanted valve size
Labeled valve size
19–21 23 25 33
AVR (n ¼ 400) 102 (25%) 151 (38%) 147 (37%) —
MVR (n ¼ 282) — — 121 (43%) 161 (57%)
AVR, Aortic valve replacement; MVR, mitral valve replacement.
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TABLE E2. Univariate predictors of outcome after aortic or mitral
valve replacement
Variable P value
Aortic valve replacement
Major thromboembolism
Concomitant coronary artery bypass grafting .002
Diabetes mellitus .04
New York Heart Association functional class .2
Left ventricular ejection fraction<35% .04
Previous valve surgery .1
Hemorrhage
Atrial fibrillation .2
Chronic obstructive pulmonary disease .02
New York Heart Association functional class .1
Left ventricular ejection fraction<35% .05
Previous cerebrovascular accident .003
Previous valve surgery .2
Valve-related reoperation
Age (per increasing year) .06
Chronic obstructive pulmonary disease <.001
Previous cerebrovascular accident .05
Valve-related mortality
Age (per increasing year) .1
Diabetes mellitus .1
Indexed effective orifice area .1
Previous cerebrovascular accident .03
Renal failure .1
Late mortality
Atrial fibrillation <.001
Age (per increasing year) .007
Diabetes mellitus .02
Indexed effective orifice area <.001
New York Heart Association functional class .2
Left ventricular ejection fraction<35% .06
Previous cerebrovascular accident .1
Prosthesis size .2
Renal function .004
Mitral valve replacement
Major thromboembolism
Chronic obstructive pulmonary disease .1
Prosthesis size .2
Hemorrhage
Concomitant coronary artery bypass grafting .01
Diabetes mellitus .1
New York Heart Association functional class .2
Valve-related reoperation
Indexed effective orifice area .2
Previous valve surgery .04
Valve-related mortality —
Late mortality
Age (per increasing year) .007
Concomitant coronary artery bypass grafting .002
Left ventricular ejection fraction<35% .02
Previous coronary artery bypass grafting .02
Renal function .001
TABLE E3. Multivariate predictors of outcome after aortic valve
replacement
Variable
Hazard ratio (95%
confidence interval) P value
Major thromboembolism
Concomitant CABG 5.3 (1.4–20.2) .02
Hemorrhage — —
Valve-related reoperation
Age (per increasing year) 0.9 (0.8–1.0) .04
Valve-related mortality — —
Late survival
Age (per increasing year) 1.1 (1.0–1.1) .007
Preoperative atrial fibrillation 3.7 (1.2–11.7) .02
CABG, Coronary artery bypass grafting.
TABLE E4. Multivariate predictors of outcome after mitral valve
replacement
Variable
Hazard ratio (95%
confidence interval)
P
value
Major thromboembolism — —
Hemorrhage
Concomitant CABG 4.6 (1.1–19.0) .04
Valve-related reoperation — —
Valve-related mortality — —
Late survival
Concomitant CABG 3.6 (1.1–11.9) .03
Left ventricular ejection
fraction<35%
4.9 (1.6–14.8) .005
Prior CABG 3.7 (1.2–12.0) .03
Renal dysfunction 3.7 (1.2–11.2) .02
CABG, Coronary artery bypass grafting.
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